Downstream processing of oligonucleotides: meeting regulatory and commercial demands
P Putaj, J Jackson, M del Carme Pons Royo et al.
Scaling AAV manufacturing across fixed-bed bioreactors: lessons from Novartis
A Khorran, X Cui, D Knutson
Identifying and addressing key regulatory risks affecting cell therapy programs
C Chen, M Brewer, M Tejada et al.